Two new Ebola vaccines have passed clinical trials against the strain of the deadly virus that caused the recent outbreak in West Africa.
A single shot of the vaccine worked against Ebola and appears to have no side effects. Macaque monkeys, a breed of monkeys closely related to humans were tested. The monkeys were injected with the Ebola virus from the current outbreak showed no signs of adverse reactions to the vaccines on vaccination. Whereas, unvaccinated monkeys injected with the Ebola virus died within a week.
Profectus BioSciences, a clinical-stage biotechnology company, is working on the development of the vaccines and are put on use as they are effective but clinical trials in humans are yet to be started.
The strain of vesicular stomatitis virus (VSV) virus is weakened and rVSV, a recombinant version has been modified to produce a protein. The protein interrogates with the virus, making it ineffective.